Attached files
| file | filename |
|---|---|
| EX-99.6 - EXHIBIT 99.6 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-6.htm |
| EX-99.4 - EXHIBIT 99.4 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-4.htm |
| EX-99.3 - EXHIBIT 99.3 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-3.htm |
| EX-99.2 - EXHIBIT 99.2 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-1.htm |
| 8-K - FORM 8-K - ALBANY MOLECULAR RESEARCH INC | v440429_8k.htm |
Exhibit 99.5
Balance sheet 31.12.2015
| (in thousands of Euro) | 31
December 2015 Consolidated Lauro 57 IFRS | Deconsolidation Lauro 57 | 31
December 2015 Consolidated Euticals IFRS | ADJ R&D | 31
December 2015 Consolidated Euticals IFRS ADJ | |||||||||||||||
| Intangible assets | 117,306 | (91,997 | ) | 25,309 | (8,831 | ) | 16,478 | |||||||||||||
| Tangible assets | 78,458 | - | 78,458 | 78,458 | ||||||||||||||||
| Deferred tax assets | 13,206 | - | 13,206 | 2,714 | 15,919 | |||||||||||||||
| Other non-current assets | 2,225 | - | 2,225 | 2,225 | ||||||||||||||||
| Total non-current assets | 211,195 | (91,997 | ) | 119,198 | (6,117 | ) | 113,081 | |||||||||||||
| Inventories | 61,187 | - | 61,187 | 61,187 | ||||||||||||||||
| Trade receivables | 42,957 | 0 | 42,957 | 42,957 | ||||||||||||||||
| Current tax receivables | 1,270 | (61 | ) | 1,209 | 1,209 | |||||||||||||||
| Other current assets | 3,782 | (20 | ) | 3,762 | 3,762 | |||||||||||||||
| Cash and cash equivalents | 26,522 | (77 | ) | 26,445 | 26,445 | |||||||||||||||
| Total current assets | 135,717 | (157 | ) | 135,560 | - | 135,560 | ||||||||||||||
| Asset of disposal group classified as held for sale | 2,055 | - | 2,055 | 2,055 | ||||||||||||||||
| Total assets | 348,967 | (92,154 | ) | 256,813 | (6,117 | ) | 250,696 | |||||||||||||
| Share capital | 58,333 | (17,505 | ) | 40,828 | 40,828 | |||||||||||||||
| Share premium reserve | 171,667 | (147,276 | ) | 24,391 | 24,391 | |||||||||||||||
| Other reserves | (10,699 | ) | 73,961 | 63,262 | 63,262 | |||||||||||||||
| Profit (loss) carried forward | (33,085 | ) | (4,502 | ) | (37,587 | ) | (6,320 | ) | (43,907 | ) | ||||||||||
| Profit (loss) for the period | 1,600 | 10 | 1,609 | 202 | 1,811 | |||||||||||||||
| Net equity | 187,816 | (95,313 | ) | 92,504 | (6,117 | ) | 86,385 | |||||||||||||
| Non-current financial liabilities | 58,651 | - | 58,651 | 58,651 | ||||||||||||||||
| Liabilities for employees’ benefits | 10,595 | - | 10,595 | 10,595 | ||||||||||||||||
| Non-current provisions for risks and charges | 8,045 | - | 8,045 | 8,045 | ||||||||||||||||
| Other non-current liabilities | (0 | ) | - | (0 | ) | (0 | ) | |||||||||||||
| Deferred tax liabilities | - | - | - | - | ||||||||||||||||
| Total non-current liabilities | 77,290 | - | 77,290 | - | 77,290 | |||||||||||||||
| Current financial liabilities | 35,821 | 3,061 | 38,882 | 38,882 | ||||||||||||||||
| Trade payables | 30,667 | (81 | ) | 30,586 | 30,586 | |||||||||||||||
| Tax payables | 3,014 | (57 | ) | 2,958 | 2,958 | |||||||||||||||
| Current provisions for risks and charges | 256 | - | 256 | 256 | ||||||||||||||||
| Other current payables | 13,459 | 234 | 13,693 | 13,693 | ||||||||||||||||
| Total current liabilities | 83,217 | 3,158 | 86,375 | - | 86,375 | |||||||||||||||
| Total liabilities | 160,507 | 3,158 | 163,665 | - | 163,665 | |||||||||||||||
| Liabilities of disposal group classified as held for sale | 644 | - | 644 | 644 | ||||||||||||||||
| Total equity and liabilities | 348,967 | (92,154 | ) | 256,813 | (6,117 | ) | 250,696 | |||||||||||||
Profit & Loss 31.12.2015
| (in thousands of Euro) | 31 December 2015 Consolidated Lauro 57 IFRS | Deconsolidation Lauro 57 | 31 December 2015 Consolidated Euticals IFRS | ADJ R&D | 31 December 2015 Consolidated Euticals IFRS ADJ | |||||||||||||||
| Revenues | 214,863 | 0 | 214,863 | 214,863 | ||||||||||||||||
| Other revenue and income | 3,338 | (123 | ) | 3,215 | 3,215 | |||||||||||||||
| Total Revenues and incomes | 218,201 | (123 | ) | 218,078 | 218,078 | |||||||||||||||
| Raw, ancillary and consumable materials and goods | (80,544 | ) | - | (80,544 | ) | (80,544 | ) | |||||||||||||
| Service costs and costs of third-party assets | (48,590 | ) | 333 | (48,257 | ) | (48,257 | ) | |||||||||||||
| Employee expenses | (56,078 | ) | 0 | (56,078 | ) | (56,078 | ) | |||||||||||||
| Other operating expenses | (2,171 | ) | 9 | (2,162 | ) | (2,162 | ) | |||||||||||||
| Change in inventories | (5,193 | ) | - | (5,193 | ) | (5,193 | ) | |||||||||||||
| Capitalization of internal costs | 3,939 | - | 3,939 | (4,664 | ) | (725 | ) | |||||||||||||
| Depreciation, Amortization and Asset value adjustments | (20,406 | ) | 39 | (20,368 | ) | 4,963 | (15,405 | ) | ||||||||||||
| Total operating costs | (209,044 | ) | 380 | (208,663 | ) | 299 | (208,364 | ) | ||||||||||||
| Operating profit | 9,157 | 258 | 9,416 | 299 | 9,714 | |||||||||||||||
| EBITDA | 29,564 | 220 | 29,784 | (4,664 | ) | 25,119 | ||||||||||||||
| Financial income | 371 | (0 | ) | 371 | 371 | |||||||||||||||
| Financial expenses | (6,254 | ) | (219 | ) | (6,472 | ) | (6,472 | ) | ||||||||||||
| Profit (loss) before taxes | 3,275 | 40 | 3,314 | 299 | 3,612 | |||||||||||||||
| Income taxes | (1,675 | ) | (30 | ) | (1,704 | ) | (97 | ) | (1,801 | ) | ||||||||||
| Net profit (loss) from operations | 1,600 | 9 | 1,609 | 202 | 1,811 | |||||||||||||||